Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Pharmaxis Ltd ( (AU:SNT) ).
Syntara Limited reported a successful quarter with significant progress in its drug development pipeline, particularly for amsulostat. The company presented positive interim Phase 2 data for amsulostat in myelofibrosis at the European Hematology Association Conference and initiated a Phase 1c/2 study for myelodysplastic syndrome. The FDA granted Fast Track designation for amsulostat, and the WHO assigned it an International Non-Proprietary Name. Syntara also began dosing patients in a trial for a keloid scar treatment. The company maintains a strong cash position, and its strategic focus on non-dilutive funding and expanding indications for amsulostat is expected to generate significant interest from investors and partners.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.12 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Syntara Limited is a clinical-stage drug development company focusing on advancing treatments for hematological cancers and other diseases. The company is actively involved in developing amsulostat, a promising drug for myelofibrosis and myelodysplastic syndrome, and is also exploring treatments for keloid scars.
Average Trading Volume: 9,903,436
Technical Sentiment Signal: Sell
Current Market Cap: A$92.68M
Find detailed analytics on SNT stock on TipRanks’ Stock Analysis page.